Immatics (IMTX) to Release Quarterly Earnings on Tuesday

Immatics (NASDAQ:IMTX) is expected to be issuing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $9.7930 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 12:30 PM ET.

Immatics (NASDAQ:IMTX) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.14. The company had revenue of $23.18 million during the quarter, compared to the consensus estimate of $12.18 million. Immatics had a negative net margin of 411.90% and a negative return on equity of 41.81%. On average, analysts expect Immatics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immatics Stock Performance

Shares of NASDAQ:IMTX traded down $0.22 during midday trading on Tuesday, reaching $10.93. 219,242 shares of the company’s stock were exchanged, compared to its average volume of 426,446. The company’s 50 day simple moving average is $10.29 and its two-hundred day simple moving average is $10.11. The firm has a market capitalization of $1.46 billion, a PE ratio of -5.94 and a beta of 1.31. Immatics has a 12 month low of $3.94 and a 12 month high of $12.41.

Institutional Investors Weigh In On Immatics

Several large investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. grew its holdings in shares of Immatics by 10.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company’s stock worth $225,322,000 after purchasing an additional 2,075,987 shares during the last quarter. Virtus Investment Advisers LLC grew its holdings in Immatics by 43.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 26,497 shares of the company’s stock worth $278,000 after acquiring an additional 7,965 shares during the last quarter. SummitTX Capital L.P. grew its holdings in Immatics by 117.7% during the 4th quarter. SummitTX Capital L.P. now owns 96,784 shares of the company’s stock worth $1,016,000 after acquiring an additional 52,318 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in Immatics during the 4th quarter worth about $575,000. Finally, Sphera Funds Management LTD. grew its holdings in Immatics by 47.7% during the 4th quarter. Sphera Funds Management LTD. now owns 861,105 shares of the company’s stock worth $9,042,000 after acquiring an additional 278,000 shares during the last quarter. Institutional investors own 64.41% of the company’s stock.

Wall Street Analysts Forecast Growth

IMTX has been the subject of a number of analyst reports. Wall Street Zen downgraded shares of Immatics from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a report on Thursday, January 22nd. TD Cowen began coverage on shares of Immatics in a report on Tuesday, April 28th. They issued a “buy” rating on the stock. Jefferies Financial Group began coverage on shares of Immatics in a report on Monday, March 16th. They issued a “buy” rating and a $18.00 target price on the stock. Finally, Mizuho set a $25.00 target price on shares of Immatics in a report on Thursday, February 19th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Immatics has an average rating of “Moderate Buy” and a consensus target price of $19.00.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.